

Videoconference

2021 Half-Year financial results

April-September, 2021



*New Drug Application

 In partnership with Teva Pharmaceuticals

 Supported by the Bill & Melinda Gates Foundation

 In partnership with AIC

 Supported by Unitaid

 Internal programs

 Animal Health product
(different clinical development process)



*New Drug Application

 In partnership with Teva Pharmaceuticals

 In partnership with AIC

 Internal programs

 Supported by the Bill & Melinda Gates Foundation

 Supported by Unitaid

 Animal Health product
(different clinical development process)



*New Drug Application

 In partnership with Teva Pharmaceuticals

 In partnership with AIC

 Internal programs

 Supported by the Bill & Melinda Gates Foundation

 Supported by Unitaid

 Animal Health product
(different clinical development process)



*New Drug Application

 In partnership with Teva Pharmaceuticals

 In partnership with AIC

 Internal programs

 Supported by the Bill & Melinda Gates Foundation

 Supported by Unitaid

 Animal Health product
(different clinical development process)



*New Drug Application

In partnership with Teva Pharmaceuticals


In partnership with AIC

Internal programs

Supported by the Bill & Melinda Gates Foundation

Supported by Unitaid

Animal Health product
(different clinical development process)



*New Drug Application

 In partnership with Teva Pharmaceuticals

 Supported by the Bill & Melinda Gates Foundation

 In partnership with AIC

 Supported by Unitaid

 Internal programs

 Animal Health product
(different clinical development process)

Finance results – First semester (April-Sept 2021)

Revenue: 4,1 M€

Operating expenses: 15,3 M€

Cash consumption from operations: 11,3 M€

Available Cash as of September 30, 2021

34,4 M€ in cash

3,0 M€ in non risky financial assets



Thank you

MedinCell
3, rue des frères Lumière
34830 Jacou • France

www.medincell.com